| Literature DB >> 31928088 |
Stian Svenøy1,2, Leiv Otto Watne3, Ingvild Hestnes1, Marianne Westberg1, Jan Erik Madsen1,2, Frede Frihagen1.
Abstract
Background and purpose - We established a care pathway for hip fracture patients, a "Hip Fracture Unit" (HFU), aiming to provide better in-hospital care and thus improve outcome. We compared the results after introduction of the HFU with a historical control group.Patients and methods - The HFU consisted of a series of measures within the orthopedic ward, such as reducing preoperative waiting time, increased use of nerve blocks, early mobilization, and osteoporosis treatment. 276 patients admitted from May 2014 to May 2015 constituted the HFU group and 167 patients admitted from September 2009 to January 2012 constituted the historical control group. Patients were followed prospectively up to 12 months post fracture.Results - Mean preoperative waiting time was 24 hours in the HFU group and 29 hours in the control group (p = 0.003). 123 patients (47%) in the HFU were started on anti-osteoporosis treatment while in hospital. "Short Physical Performance Battery" score (SPPB) was mean 5.5 in the HFU group and 3.8 in the control group at 4 months (p < 0.001), and 5.7 vs. 3.6 at 12 months (p < 0.001). The mortality rate at 4 months was 15% in both groups. No statistically significant differences were found in readmissions, complications, new nursing home admissions, in Barthel ADL index or a mental capacity test at the follow-ups.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31928088 PMCID: PMC7144204 DOI: 10.1080/17453674.2019.1710804
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Ward description
| Description of the orthopedic ward n | |
|---|---|
| Number of beds | 52 |
| Staff order, numbers per bed | |
| Nurses | 1.2 |
| Nursing assistants | 0.06 |
| Physiotherapists | 0.07 |
| Occupational therapists | 0 |
| Nutritionists | 0 |
| Social worker | 0.02 |
Results for the Hip Fracture Unit (HFU) during hospital stay. Values are frequency (%) unless otherwise specified
| Variable | Aim (%) | Results |
|---|---|---|
| Number of patients | – | 276 |
| Preoperative femoral nerve block | – | 155/260 (60) |
| Mean (SD) preoperative waiting time, h | – | 24 (12) |
| Operated within 48 h | (100) | 260/271 (96) |
| Operated within 24 h | (> 80) | 157/272 (58) |
| Mobilization started within first day after surgery | (100) | 220/240 (92) |
| Urethral catheter removed before 36 hours post-surgery | (> 80) | 147/250 (59) |
| Started anti-osteoporosis drug treatment during stay | (> 80) | 123/264 (47) |
| Admitted to other orthopedic wards than the HFU ward | None | 62/276 (22) |
| Duration of hospital stay, median days (range) | 5–7 | 5 (2–30) |
Total number reduced due to missing data.
For anti-osteoporosis drugs used, see Table 3
Results and complications before and after introduction of the Hip Fracture Unit
| Variable | HFU group n = 276 | Control group n = 167 | Relative risk and/or (CI) |
|---|---|---|---|
| Waiting time before surgery, mean h | 24 | 29 | (1.6–7.6) |
| Operated within 48 hours, n (%) | 260/271 (96) | 139/163 (85) | 1.1 (1.0–1.2) |
| Operated within 24 hours, n (%) | 157/271 (58) | 83/163 (51) | 1.1 (0.9–1.4) |
| Started anti-osteoporosis drug | |||
| treatment during stay, n (%) | 123/273 (47) | 1 (0.5) | |
| Zoledronic acid | 95 | 1 | |
| Alendronate | 3 | 0 | |
| Denosumab | 25 | 0 | |
| Days of hospital stay, median (range) | 5 (2–30) | 8 (1–39) | (2.2–3.7) |
| Postoperative surgical complications, n (%) | 22 (8) | 8 (5) | 1.6 (0.7–3.6) |
| Deep wound infection | 9 | 1 | |
| Prosthetic dislocation | 2 | 3 | |
| Fixation failure | 6 | 3 | |
| Other | 5 | 1 | |
| Readmitted in 30 days, n (%) | 32/271 (12) | 13/165 (8) | 1.5 (0.8–2.7) |
| Reoperated at 4 months, n (%) | 16/276 (6) | 5/164 (3) | 1.9 (0.7–5.1) |
| at 12 months (accumulated), n (%) | 18/276 (7) | 9/164 (6) | 1.2 (0.5–2.5) |
| New admissions to a permanent care | |||
| facility at 4 months, n (%) | 41/172 (24) | 18/83 (22) | 1.1 (0.6–1.7) |
| Dead at 4 months | 43 (15) | 25 (15) | 1.0 (0.6–1.6) |
| Dead at 12 months | 63 (23) | 43 (26) | 0.9 (0.9–1.1) |
Other surgical complications were: 1 trochanteric avulsion. 1 peroneal nerve palsy. 1 reoperated for hematoma. 1 hemiarthroplasty had soft tissue interposed in the acetabulum. 1 reoperated for gluteus medius insufficiency. 1 had a skin laceration of the leg after a fall in the ward.
Patients who lived in a permanent care facility preoperatively were excluded.

Patient inclusion and follow-up. Randomized to “usual care” in the orthopedic ward in original study (165 patients were randomized to admission in the geriatric ward and are not included in the present study). In addition, 11 patients at 4 months and 5 patients at 12 months are missing scores due to surgeons other than SS and FF seeing the patients.
Baseline characteristics of the Hip Fracture Unit (HFU) care pathway and the historical control group. Values are frequency (%) unless otherwise specified
| Baseline characteristics | HFU intervention group n = 276 | OOT |
|---|---|---|
| Female sex | 185 (67) | 129 (77) |
| Age | 81 (11) [80–82] | 82 (10) [81–84] |
| median (range) | 84 (49–98) | 85 (46–101) |
| ASA | 2.6 (0.7) [2.5–2.7] | 2.6 (0.6) [2.5–2.7] |
| Living in institution | 59 (21) | 51 (30) |
| Type of fracture | ||
| Femoral neck | 151 (56) | 98 (59) |
| Trochanteric | 113 (42) | 67 (40) |
| Subtrochanteric | 5 (2) | 2 (1) |
| Surgical procedure | ||
| Arthroplasty | 127 (46) | 72 (43) |
| Osteosynthesis | 149 (54) | 91 (55) |
| Not operated | 0 (0) | 4 (2) |
| Duration of surgery, min | 71 (31) [67–74] | 77 (43) [71–84] |
Oslo Orthogeriatric Trial.
Values are mean (SD) [95% CI]
Functional outcome at 4 and 12 months postoperatively. Values are mean (SD)
| Variable | HFU group | Control group | (CI) | Adjusted analysis | |
| p-value | B (CI) | ||||
| 4 months results | |||||
| SPPB | 5.5 (4.7) | 3.8 (3.4) | (0.7 to 2.6) | 0.03 | 0.9 (0.1 to 1.7) |
| CERAD | 13.3 (7.6) | 11.4 (7.5) | (0.1 to 3.7) | 0.5 | 0.5 (–0.9 to 1.9) |
| Barthel ADL | 15.7 (5.2) | 14.6 (5.5) | (–0.1 to 2.2) | 0.8 | –0.1 (–1.1 to 0.9 |
| 12 months results | |||||
| SPPB | 5.7 (4.7) | 3.6 (3.3) | (0.5 to 1.1) | 0.02 | 1.0 (0.2 to 2.0) |
| CERAD | 14.2 (8.3) | 11.5 (8.4) | (0.4 to 4.8) | 0.8 | 0.2 (–1.5 to 1.8) |
| Barthel ADL | 16.6 (4.8) | 14.3 (5.6) | (0.9 to 3.5) | 0.1 | 0.9 (–0.1 to 2.0) |
Short Physical Performance Battery (SPPB) scale 0–12, Consortium to Establish a Registry for Alzheimer’s disease (CERAD) scale 0–30, Barthel Activities of Daily Life (ADL) scale 0–20.
Linear regression on mean difference adjusted for age, gender, ASA, and pre-fracture accommodation (living in institution or home-dwelling).